Navigation Links
Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
Date:11/17/2010

DALLAS and NEW YORK, Nov. 17, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.  The poster being displayed, entitled "Vitamin B-12 Nanoparticles for the Targeted Delivery of RNAi Therapeutics", summarizes key findings of the Company's rebranded Cobalamin program, CobaCyte for RNAi.  The second poster, entitled "Preclinical and Clinical Studies of ProLindac: A Novel Polymer Prodrug of DACH Platinum", details the distinct attributes and advantages of utilizing Access' second generation DACH Platinum, ProLindac.

"We are pleased to be included in this year's Innovations in Cancer Prevention and Research Conference as the team's research in both programs support a significant opportunity in treating various cancers," said David Nowotnik, Senior VP of Research and Development, Access Pharmaceuticals, Inc.  He continued, "Given the recently commenced combination trial for ProLindac and the heightened interest surrounding our CobaCyte program, this conference, with its astute multidisciplinary audience, is an ideal venue to display the work currently under development at Access."

The conference is organized by the Cancer Prevention and Research Institute of Texas (CPRIT).

For information on the conference, please visit: http://cpritconference2010.eventbrite.com/

Access Pharmaceuticals recently received $1.5 million in government grants under the Qualifying Therapeutic Discovery Project (QTDP).  The Company's ProLindac and CobaCyte programs each received a $245,000 grant.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), for the management of patients with mucositis, ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.

The company also has other advanced drug delivery technologies including CobaCyte-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
2. Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th
3. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
4. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
5. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
6. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
7. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
8. Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases
9. The Development of Medical Foundations in the San Diego Area will Restrict Physician Access for Pharmaceutical Reps
10. Recent Patient Series Demonstrates Spirus Medicals Power Spiral Endoscope Enables Unprecedented Access to GI Tract
11. Utahs Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016 Orthopedic Implants (Including Spinal Implants, ... to Gain a Significant Market Share Owing to a Large ... ... According to a new report by Persistence ... Packaging: Clamshell Product Type Segment Projected to Witness a Significantly ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended the trading ... edged 0.36% higher, to finish at 19,191.93; and the S&P ... as six out of nine sectors ended the day in ... Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ), ... Inc. (NASDAQ: INCR ), and La Quinta Holdings ...
Breaking Medicine Technology:
(Date:12/2/2016)... NJ (PRWEB) , ... December 02, 2016 , ... Sourced ... Water has some unique properties including its unmatched natural purity of just 6 ppm ... clean and crisp. , Nothing Water has been available in several ShopRite and FoodTown ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, Inc., the ... million in an initial round of funding. The round was led by experienced ... can receive far better care through the application of the best technologies from ...
(Date:12/2/2016)... FL (PRWEB) , ... December 02, 2016 , ... ‘Tis ... are winners of $1,000 each from the National Family Partnership and the Drug Enforcement ... families who decorated their homes and the 10 winning schools who decorated their campuses ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... tech functions and stylish design wanted by today’s consumers at an affordable price, ... Darin Philip says the new watch is “a game changer” when it comes ...
Breaking Medicine News(10 mins):